论文部分内容阅读
继亚胺培南(imipenem)、panipenem之后,新的碳杂青霉烯类抗生素meropenem已由日本住友化学公司开发问世。原有碳杂青霉烯类抗生素对人脱氢肽酶Ⅰ(DHP—Ⅰ)不稳定,具有肾毒性,需与西司他丁(cilastatin)及氨基酸联用。与之相比,本品对DHP-Ⅰ稳定,肾毒性轻,具有可单独用药的特点。从结构上来看,本品1位上引入了甲基,2位上引入了脯氨酸侧链。本品对革兰氏阳性菌、革兰氏阴性菌及厌氧菌均有广范围的抗菌谱,特别是对包括绿脓杆菌的葡萄糖非发酵性革兰氏阴性菌显示出强抗菌力。对β-内酰胺酶稳定。人血浆
Following imipenem, panipenem, the new carbapenem antibiotic meropenem has been developed by Sumitomo Chemical Japan. The original carbapenem antibiotics on human dehydropeptidase Ⅰ (DHP-Ⅰ) instability, with nephrotoxicity, need to be combined with cilastatin (cilastatin) and amino acids. In contrast, this product is stable to DHP-Ⅰ, nephrotoxic light, with a single drug can be used. From the structural point of view, this product introduced a methyl on the 1st, 2 introduced the proline side chain. The product of Gram-positive bacteria, Gram-negative bacteria and anaerobic bacteria have a wide range of antibacterial spectrum, especially for Pseudomonas aeruginosa glucose non-fermentative Gram-negative bacteria showed strong antibacterial. Β-lactamase stable. Human plasma